Can Tumor Necrosis Factor Receptor II Gene 676T>G Polymorphism Predict the Response Grading to Anti-TNFalpha Therapy in Rheumatoid Arthritis?

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2008 Mar 1

PMID 18309487

Citations 14

Authors

Alessia Ongaro

Monica De Mattei

Agnese Pellati

Angelo Caruso

Stefano Ferretti

Federica Francesca Masieri

Maria Fotinidi

Ilaria Farina

Francesco Trotta

Melissa Padovan

Affiliations

Soon will be listed here.

Abstract

In this study we analyzed whether the polymorphisms 676T>G in the tumor necrosis factor receptor (TNFR) II gene and -308G>A in the TNFalpha promoter gene may influence the response grading to anti-TNFalpha therapy in rheumatoid arthritis. We enrolled and genotyped 105 RA patients treated with etanercept (n = 55), infliximab (n = 40) and adalimumab (n = 10) for 1 year. The clinical response was evaluated according to the ACR criteria every 3 months. Patients with TNFRII 676TG genotype was significantly associated with lower ACR response compared with 676TT genotype, at 3 (OR 3.78 95% CI 1.07-13.31) and 12 months (OR 4.30 95% CI 1.16-15.99) of treatment. No significant association between TNFalpha -308G>A polymorphism and the clinical response was found. TNFRII 676TG genotype is associated with a lower response to anti-TNFalpha therapy, independently from the specific agent used. This polymorphism could become a useful genetic marker for predicting the different response grading to anti-TNFalpha therapy.

Citing Articles

Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.

Aluko A, Ranganathan P Methods Mol Biol. 2022; 2547:527-567.

PMID: 36068476 DOI: 10.1007/978-1-0716-2573-6_19.

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.

Lim S, Kim K, Choi C J Pers Med. 2022; 12(8).

PMID: 36013214 PMC: 9410311. DOI: 10.3390/jpm12081265.

Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.

Jezernik G, Gorenjak M, Potocnik U Biomedicines. 2022; 10(8).

PMID: 36009355 PMC: 9404936. DOI: 10.3390/biomedicines10081808.

Toward Overcoming Treatment Failure in Rheumatoid Arthritis.

Wang Z, Huang J, Xie D, He D, Lu A, Liang C Front Immunol. 2022; 12:755844.

PMID: 35003068 PMC: 8732378. DOI: 10.3389/fimmu.2021.755844.

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics.

Conti V, Corbi G, Costantino M, De Bellis E, Manzo V, Sellitto C Biomolecules. 2020; 10(12).

PMID: 33327600 PMC: 7765045. DOI: 10.3390/biom10121672.

References

Reddy P, Slack J, Davis R, Cerretti D, Kozlosky C, Blanton R . Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem. 2000; 275(19):14608-14. DOI: 10.1074/jbc.275.19.14608. View

van der Helm-van Mil A, Dieude P, Schonkeren J, Cornelis F, Huizinga T . No association between tumour necrosis factor receptor type 2 gene polymorphism and rheumatoid arthritis severity: a comparison of the extremes of phenotypes. Rheumatology (Oxford). 2004; 43(10):1232-4. DOI: 10.1093/rheumatology/keh314. View

Kang C, Lee K, Yoo D, Kang C, Bae S . The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(4):547-52. DOI: 10.1093/rheumatology/keh550. View

Miterski B, Drynda S, Boschow G, Klein W, Oppermann J, Kekow J . Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet. 2004; 5:2. PMC: 356909. DOI: 10.1186/1471-2156-5-2. View

Brennan F, Maini R, Feldmann M . TNF alpha--a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 1992; 31(5):293-8. DOI: 10.1093/rheumatology/31.5.293. View

Suryaprasad A, Prindiville T . The biology of TNF blockade. Autoimmun Rev. 2003; 2(6):346-57. DOI: 10.1016/s1568-9972(03)00048-x. View

Engelmann H, Novick D, Wallach D . Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265(3):1531-6. View

Aguillon J, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M . Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?. Immunobiology. 2006; 211(1-2):75-84. DOI: 10.1016/j.imbio.2005.09.005. View

Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D . Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005; 52(9):2693-6. DOI: 10.1002/art.21266. View

10.

Pantelidis P, Lympany P, Foley P, Fanning G, Welsh K, du Bois R . Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2. Tissue Antigens. 2000; 54(6):585-91. DOI: 10.1034/j.1399-0039.1999.540608.x. View

11.

Glossop J, Dawes P, Nixon N, Mattey D . Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther. 2005; 7(6):R1227-34. PMC: 1297570. DOI: 10.1186/ar1816. View

12.

Cuenca J, Cuchacovich M, Perez C, Ferreira L, Aguirre A, Schiattino I . The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology (Oxford). 2003; 42(2):308-13. DOI: 10.1093/rheumatology/keg092. View

13.

Ollier W, Villarreal J, Ordi J, Teh L, Hajeer A . Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens. 2000; 55(1):97-9. DOI: 10.1034/j.1399-0039.2000.550122.x. View

14.

Seitz M, Wirthmuller U, Moller B, Villiger P . The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2006; 46(1):93-6. DOI: 10.1093/rheumatology/kel175. View

15.

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

16.

Bayley J, Bakker A, Kaijzel E, Huizinga T, Verweij C . Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. Rheumatology (Oxford). 2003; 42(8):969-71. DOI: 10.1093/rheumatology/keg267. View

17.

Fonseca J, Carvalho T, Cruz M, Nero P, Sobral M, Mourao A . Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis. 2005; 64(5):793-4. PMC: 1755496. DOI: 10.1136/ard.2004.028167. View

18.

Lee Y, Rho Y, Choi S, Ji J, Song G . Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2006; 27(2):157-61. DOI: 10.1007/s00296-006-0175-7. View

19.

Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D . Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2007; 35(6):435-40. DOI: 10.1080/03009740600904284. View

20.

Bouma G, Crusius J, Oudkerk Pool M, Kolkman J, von Blomberg B, Kostense P . Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol. 1996; 43(4):456-63. DOI: 10.1046/j.1365-3083.1996.d01-65.x. View